The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.

about

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.

Item

http://www.wikidata.org/entity/Q54982443

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The incidence and management o ...... th factor receptor inhibitors.

@en

The incidence and management o ...... th factor receptor inhibitors.

@nl

type

Item

label

The incidence and management o ...... th factor receptor inhibitors.

@en

The incidence and management o ...... th factor receptor inhibitors.

@nl

prefLabel

The incidence and management o ...... th factor receptor inhibitors.

@en

The incidence and management o ...... th factor receptor inhibitors.

@nl

P1476

The incidence and management o ...... th factor receptor inhibitors.

@en

P2093

Aldona Maciąg

http://www.w3.org/2001/XMLSchema#string

Aleksandra Lesiak

http://www.w3.org/2001/XMLSchema#string

Elwira Paluchowska

http://www.w3.org/2001/XMLSchema#string

Luiza Marek-Józefowicz

http://www.w3.org/2001/XMLSchema#string

Magdalena Ciążyńska

http://www.w3.org/2001/XMLSchema#string

Monika Słowińska

http://www.w3.org/2001/XMLSchema#string

Rafał Czajkowski

http://www.w3.org/2001/XMLSchema#string

Witold Owczarek

http://www.w3.org/2001/XMLSchema#string

P2860

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

Trastuzumab - a monoclonal antibody - and dendrimers in a targeted therapy for breast cancer

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for hu

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

Characterizing the phenomenon of radiation recall dermatitis.

Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management.

Mechanisms of cutaneous toxicities to EGFR inhibitors.

A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

P304

418-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5114/ADA.2017.71106

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29507555

http://www.w3.org/2001/XMLSchema#string

P932

5831275

http://www.w3.org/2001/XMLSchema#string